Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Glaukos Corporation    GKOS

GLAUKOS CORPORATION

(GKOS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Glaukos: 3Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
11/06/2019 | 06:43pm EST

SAN CLEMENTE, Calif. (AP) _ Glaukos Corp. (GKOS) on Wednesday reported a loss of $13.5 million in its third quarter.

On a per-share basis, the San Clemente, California-based company said it had a loss of 37 cents. Losses, adjusted for non-recurring costs, were 10 cents per share.

The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.

The glaucoma treatments developer posted revenue of $58.5 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $56.5 million.

Glaukos expects full-year revenue in the range of $229 million to $232 million.

Glaukos shares have risen 11% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $62.36, a climb of 6% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on GKOS at https://www.zacks.com/ap/GKOS

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GLAUKOS CORPORATION
02/06GLAUKOS CORPORATION : to Release Fourth Quarter and Full Year 2019 Financial Res..
BU
02/05GLAUKOS : Financial Statements and Exhibits (form 8-K/A)
AQ
01/15GLAUKOS CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/03GLAUKOS : Announces Participation in J.P. Morgan Healthcare Conference
BU
2019GLAUKOS CORP : Completion of Acquisition or Disposition of Assets, Regulation FD..
AQ
2019GLAUKOS : Completes Acquisition of Avedro, Inc.
BU
2019GLAUKOS : Announces Participation in Piper Jaffray Healthcare Conference
BU
2019GLAUKOS CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2019GLAUKOS : 3Q Earnings Snapshot
AQ
2019GLAUKOS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
More news
Financials (USD)
Sales 2019 241 M
EBIT 2019 -26,2 M
Net income 2019 -28,3 M
Finance 2019 96,5 M
Yield 2019 -
P/E ratio 2019 -93,9x
P/E ratio 2020 -123x
EV / Sales2019 11,8x
EV / Sales2020 9,02x
Capitalization 2 941 M
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 67,13  $
Last Close Price 67,89  $
Spread / Highest target 17,8%
Spread / Average Target -1,13%
Spread / Lowest Target -16,0%
EPS Revisions
Managers
NameTitle
Thomas William Burns President, Chief Executive Officer & Director
William J. Link Chairman
Chris M. Calcaterra Chief Operating Officer
Joseph E. Gilliam CFO, CAO & Senior VP-Corporate Development
L. Jay Katz Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAUKOS CORPORATION23.61%2 941
STRYKER CORPORATION5.71%83 129
SMITH & NEPHEW PLC-0.30%20 788
WRIGHT MEDICAL GROUP N.V.-0.16%3 911
INSPIRE MEDICAL SYSTEMS, INC.8.57%1 885
AXONICS MODULATION TECHNOLOGIES, INC.23.75%1 174